lhasalimited.org

What It Is

Lhasa Limited provides in silico scientific software for chemical safety decision-making, with a focus on life sciences, pharmaceuticals, chemical safety, and regulatory assessment teams. Its website content centers on carcinogenicity assessment scenarios, emphasizing the use of software, expert knowledge, data sharing, and alignment with regulatory frameworks to help reduce or replace long-term animal studies and produce transparent, auditable risk assessment conclusions.

Core Features and Modules

Its offering is not a single tool, but a set of specialized modules. LCDB Plus is designed for querying, evaluating, and calculating carcinogenicity data and TD50 values; Vitic provides public and proprietary toxicity data, supporting structure, substructure, and similarity searches; Derek Nexus uses more than 40 years of SAR knowledge to identify potential structural alerts for carcinogenic toxicity; and Kaptis organizes evidence through AOP adverse outcome pathways, supporting weight-of-evidence assessment, confidence judgments, identification of knowledge gaps, and report generation. The overall workflow covers “defining the substance and context — prediction and mechanistic interpretation — evidence integration — preparation of regulatory documentation.”

Pricing, Trial, and Deployment

The main content does not disclose plans, pricing, licensing models, payment methods, or deployment options, and only provides an option to request a demo. Notably, the Lhasa Carcinogenicity Database is described as freely accessible, allowing academic and research users to use public long-term carcinogenicity study data. The page does not provide clear information on whether the product is delivered via the cloud, whether on-premises deployment is supported, or whether enterprise permissions, SSO, audit logs, APIs, or developer capabilities are available.

Pros and Cons

Its strengths lie in its professional depth, with a complete chain spanning data, prediction, mechanistic interpretation, and regulatory reporting, and explicit alignment with frameworks such as ICH S1B(R1), ICH S2, ICH S8, and REACH. For teams that need to explain scientific rationale to regulators, its transparent and traceable reporting has significant value. The limitations are that key SaaS procurement information is missing: pricing, integrations, security certifications, permission systems, and accessibility from China are not disclosed. At the same time, the product is highly oriented toward toxicology specialists, so non-expert teams may face a steep learning curve.

Who It’s For and Access from China

It is best suited to pharmaceutical R&D, toxicology, safety assessment, CMC/impurity assessment, regulatory affairs, and academic research organizations, for use in carcinogenicity weight-of-evidence assessment, ICH M7 impurity risk assessment, TD50 calculation, and preparation of regulatory materials. Its accessibility from China is unknown, and there is no clear information on payment or local support. For procurement within China, buyers should focus on confirming network availability, contract settlement, data compliance, and whether local alternatives or consulting support are available.